No class-action suit over Vioxx, judge rules

Share this article:
A federal judge denied a request by users of Merck’s withdrawn painkiller Vioxx to pool thousands of personal injury cases into a single class-action lawsuit. The order, issued by US District Judge Eldon Fallon, means that Vioxx users who claim they were injured by the drug must sue only on their own behalf. Fallon did not rule on the possibility of separate class-actions suits for each state and the District of Columbia, though. Plaintiffs had proposed trying all of the cases under the laws in New Jersey, arguing that Merck should reasonably expect to follow the laws of the state where it is headquartered. Fallon ruled that it makes more sense to apply the law of each plaintiff's home state to that plaintiff's claims. In addition, although he wrote that he was "confident that common questions exist" among the more than 7,000 remaining cases, plaintiff allegations of Merck’s negligence in failing to warn doctors about Vioxx "necessarily turn on numerous individualized issues." Merck had vowed to fight each Vioxx case individually.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...